Lord, Abbett & Co. LLC Immuno Gen, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 07, 2024	SELL	$14.09 - $19.87 $2.25 Million - $3.17 Million	-159,545 Reduced 17.36%	759,450 $12.1 Million
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $2.25 Million - $3.17 Million	-159,545 Reduced 17.36%	759,450 $12.1 Million
Q2 2023 Oct 07, 2024	BUY	$3.75 - $20.05 $3.45 Million - $18.4 Million	918,995 New	918,995 $17.3 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $3.45 Million - $18.4 Million	918,995 New	918,995 $17.3 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.